Close Menu

NEW YORK – Eurofins Genomics today announced it has acquired Blue Heron Biotech.

Blue Heron, based in Bothell, Washington, specializes in gene synthesis and DNA design.

"Since DNA oligonucleotides play an integral role in genes, the deal will bolster Blue Heron's production capabilities as well as expand Eurofins Genomics' gene portfolio into cloning and complex gene constructs," Eurofins Genomics said in a statement. The firm added that the acquisition strengthens its offerings in the synthetic biology market.

Financial and other terms of the deal were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A small, early-stage trial of a combination therapy for brain cancer reports favorable responses in two patients, according to the Guardian.

Nature News writes that viral genomic surveillance in the US faces systemic issues.

President Joe Biden is seeking an increase in federal spending, including higher budgets for the National Institutes of Health and Centers for Disease Control and Prevention.

In PLOS this week: sex-stratified genome-wide association study of chronic pain, sequencing data from Indigenous Mexican groups, and more.